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Abstract
Objectives—Bisphosphonates commonly used to treat osteoporosis, Paget’s disease, multiple
myeloma, hypercalcemia of malignancy and osteolytic lesions of cancer metastasis have been
associated with bisphosphonate-associated jaw osteonecrosis (BJON). The underlying
pathogenesis of BJON is unclear, but disproportionate bisphosphonate concentration in the jaw
has been proposed as one potential etiological factor. This study tested the hypothesis that skeletal
biodistribution of intravenous bisphosphonate is anatomic site-dependent in a rat model system.
Materials and Methods—Fluorescently labeled pamidronate was injected intravenously in
athymic rats of equal weights followed by in vivo whole body fluorimetry, ex vivo optical imaging
of oral, axial and appendicular bones and ethylenediaminetetraacetic acid bone decalcification to
assess hydroxyapatite-bound bisphosphonate.
Results—Bisphosphonate uptake and bisphosphonate released per unit calcium were similar in
oral and appendicular bones but lower than those in axial bones. Hydroxyapatite-bound
bisphosphonate liberated by sequential acid decalcification was highest in oral relative to axial and
appendicular bones (p < 0.05).
Conclusions—This study demonstrates regional differences in uptake and release of
bisphosphonate from oral, axial and appendicular bones of immune deficient rats.
Keywords
Bisphosphonate; osteonecrosis; jaw; fluorescent labeling; bone
Introduction
Bisphosphonates (BPs) are efficacious in the treatment of osteoporosis, Paget’s disease,
multiple myeloma, hypercalcemia of malignancy and osteolytic lesions of cancer metastasis.
However several nitrogen-containing bisphosphonates are associated with spontaneous jaw
necrosis (Migliorati et al., 2006, Ruggiero et al., 2006, Woo et al., 2006). While
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bisphosphonate-associated jaw osteonecrosis (BJON) is clinically similar to
osteoradionecrosis (ORN) based on characteristic tissue dehiscence, chronic bone
devitalization and lytic radiographic features, the underlying pathogenesis of BJON is still
unclear (Sarin et al., 2008).
Bisphosphonates are analogues of pyrophosphate with oxygen substituted with carbon in the
pyrophosphate bond to form a phosphate-carbon-phosphate (P-C-P) structural backbone.
Selective modification of sides chains attached to the carbon atom has produced
bisphosphonates with distinct physicochemical and biological characteristics as well as
enhanced binding affinity and anti-resorptive properties (Rodan & Fleisch, 1996). Avid
binding of bisphosphonates to hydroxyapatite keep them unmetabolized for long periods of
time (Jung et al., 1973, Fleisch, 1998). This remarkable physicochemical property is due to
binding of the phosphate ends of bisphosphonate to metal ions, including calcium to form
both soluble and insoluble complexes and the resistance of their P-C-P structural backbone
to heat, most chemicals and enzymatic hydrolysis (Fleisch, 2000). Specifically, the strong
association of intravenous nitrogen-containing bisphosphonates with BJON relative to oral
formulations suggests that intravenous administration enhances higher bisphosphonate
bioavailability. About 50% of intravenous bisphosphonates is bioavailable for incorporation
into bone matrix compared to an average of 1% of oral bisphosphonates due to delayed
gastrointestinal tract absorption (Ezra & Golomb, 2000).
It is still unclear why bisphosphonate-associated osteonecrosis is limited to the jaws.
Suggested theories focus on local factors unique to orofacial bones in health and disease
(Sarin et al., 2008, Stefanik et al., 2008, Stefanik et al., 2006), but existence of skeletal site-
disparity in biodistribution and bioavailability of bisphosphonates is yet to be fully clarified.
Additionally, it is unclear if bisphosphonates are disparately sequestered in orofacial bones
based on differential uptake and release of hydroxyapatite-bound bisphosphonate. The
premise is that higher orofacial bone uptake of bisphosphonate may potentially reach
concentrations high enough to become toxic to oral epithelium and alter normal oral tissue
healing. The present study used fluorescently tagged pamidronate (a nitrogen-containing
bisphosphonate strongly associated with BJON) to test the hypothesis that skeletal uptake
and release of bisphosphonate in rats is anatomic site-dependent. We demonstrated in
immunodeficient rats, regional differences in skeletal uptake and release of bisphosphonate
in oral, axial and appendicular bones but implications for site-selectivity of BJON and
effects of immune modulation need further clarifications.
Materials and Methods
Study animals
Four female 250 g athymic rats (NIH-RNU-F nude rats, Taconic Farms, Germantown NY)
were given intravenous bisphosphonate under animal protocol (# 801312) approved by
University of Pennsylvania Office of Regulatory Affairs.
In vivo imaging of fluorescently tagged bisphosphonate
Animals were anesthetized with parenterally administered cocktail of ketamine (37 mg/kg
body weight) and medetomidine (0.5 mg/kg body weight). Following manufacturer’s
recommendation, each animal received tail vein injection of 80 nmol/kg body weight of far
red fluorescently-tagged pamidronate (OsteoSense ™680, Cat # 10020, VisEn Medical,
Woburn, MA) in 150 μl phosphate buffered saline (PBS). Anesthesia was immediately
reversed with antipamezole (1mg/kg body weight). Twenty four hours after bisphosphonate
injection, animals were re-anesthetized, residual skin hair was shaved and images of
hydroxyapatite-bound bisphosphonate was acquired with an optical imager (Maestro ™, CRI
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Inc, Woburn, MA) using deep red filters (excitation range 671–705 nm, emission of 750 nm
long pass). Animals were positioned to capture images of upper and lower one half of the
body from ventral and dorsal views before they were sacrificed by CO2 asphyxiation.
Individual bone parts were immediately dissected free of soft tissues, shielded from light
and stored at −20°C. Using similar in vivo imaging parameters, bone parts were scanned a
second time before desorption of bound bisphosphonate (Figure 1). Bisphosphonate signal
intensity in the images were analyzed with ImageJ (version, 1.40G, National Institutes of
Health, Bethesda MD) after defining specific regions of interest (ROI) that correlate with
bone sections subsequently recovered for desorption of bound bisphosphonate (as described
below). Bisphosphonate signal intensity per unit area normalized to adjacent background
intensity was expressed as relative fluorescence units (RFU).
Desorption of hydroxyapatite-bound bisphosphonate
Bone parts were grouped into three anatomic regions: oral (mandible), appendicular
(humerus, radius/ulnar, femur, tibia/fibula) and axial (ribs, vertebrae) for comparative
analysis of bisphosphonate uptake. Left and right mandibles were analyzed separately after
removing attached teeth. Similarly, bone sections of comparatively equal weight as
mandible were analyzed from long bone diaphysis, ribs and vertebrae. Serial decalcification
to remove calcium-bound bisphosphonate was achieved with 0.5 M
ethylenediaminetetraacetic acid (EDTA), pH 8.0 at 37°C in the dark using a rotary shaker.
The EDTA solution was changed twice so that released calcium and bisphosphonate were
recovered after 24, 48 and 120 hours of consecutive decalcification (Figure 1). Recovered
fluorescently-tagged bisphosphonate was measured with a Fluorometer (Photon Technology
International, Birmingham, NJ) at wavelengths of 695 nm excitation and 700–705 nm
emission while calcium released in solution was measured with an Atomic Absorption
Spectrophotometer (PerkinElmer, Waltham, MA) at wavelength of 422.7nm. Absolute
amounts of bisphosphonate and calcium were computed from respective standard curves.
Statistical Analysis
Mean RFU was used to assess hydroxyapatite-associated fluorescence in vivo. Mean site-
specific RFU was correlated with respective bisphosphonate and calcium amounts from
corresponding bone sections. Anatomic site differences of ROIs were analyzed and
compared based on oral, axial and appendicular regions. Data was expressed as mean ±
standard deviation, analyzed by one-way analysis of variance (ANOVA) followed by Dunn-
Sidak post hoc multiple comparisons with SigmaStat 3.1 statistical package (Systat
Software, Chicago, IL, USA). Statistical significance was set at p < 0.05.
Results
Athymic rats were selected based on their nude skin since hair interferes with optical
imaging. Each rat received a metabolic dose of 60.7 μg/kg body weight bisphosphonate
(Table 1) which is approximately 4.3 mg pamidronate. Fluorescence intensity of
hydroxyapatite-bound bisphosphonate in all animals was regionally variable and stronger
than adjacent soft tissues (Figures 2A). All the bone parts demonstrated heterogeneous
labeling. There was relatively higher signal intensity in the mandibular condyle than the
relatively more homogeneous intensity in the body of mandible (Figure 2B). Similarly, there
was higher labeling intensity at proximal and distal ends of the long bones (Figure 2C),
anterior ends of the rib cage and intervertebral discs (Figure 2D). Total bisphosphonate
signal intensity in oral bone was similar to that of appendicular bone but lower than that of
axial bone (Figure 2E). Sequential and cumulative amounts of bisphosphonate released from
bone sections after three rounds of decalcification indicate significantly higher
hydroxyapatite-bound bisphosphonate (p < 0.05) in oral bones relative to axial and
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appendicular sites (Figures 3A and B). Interestingly, extractable bisphosphonate from oral
bones after 120 hours was still relatively higher than bisphosphonate extractable from either
axial or appendicular bones even at the initial 24 hour-time point (Figures 3A and B). As
expected, these regional differences were consistent with calcium serially released from the
different anatomic regions (Figure 3C and D) since bisphosphonate binds to hydroxyapatite.
Consistent with bisphosphonate signal intensity in Figure 2E, the amount of bisphosphonate
per unit calcium released in oral and appendicular bones were similar but lower than axial
bone (Figure 3E).
Discussion
BJON is an established oral complication associated with long-term treatment with nitrogen-
containing bisphosphonate (Marx et al., 2005, Migliorati et al., 2005, Woo et al., 2006).
Pathogenesis of BJON is still unclear, but proposed theories include a relatively higher
concentration of bisphosphonate in the jaws, enhanced bisphosphonate anti-osteoclastic and
anti-angiogenesis actions, possible uncoupling of osteoblast-osteoclast equilibrium and a
combination of drug, patient and oral issues acting in concert to produce a ‘band-wagon
effect’ (Sarin et al., 2008, Reid et al., 2007). To further clarify preferential bisphosphonate
concentration in the jaws, we tested and evaluated biodistribution and bioavailability of
fluorescently tagged pamidronate strongly associated with BJON because of its high affinity
for hydroxyapatite and high anti-resorptive actions. High binding affinity and immediate
skeletal binding of single doses of bisphosphonate is saturable, so that unbound drug is
rapidly eliminated by renal clearance (Rogers, 2003). About 56–66% of bisphosphonate is
retained in the skeleton within the first 6 hours (Lin et al., 1992), (Zaheer et al., 2001), so we
used fluorescently tagged pamidronate evaluable as early as 2 hours post-injection and
performed optical imaging at 24 hours to allow for adequate bisphosphonate biodistribution
as well as elimination of unbound drug.
Bisphosphonate is purported to concentrate in the jaws hundred times more than other
skeletal sites (Reid et al., 2007) possibly due to unique jaw bone architecture or vascularity;
our data support regional differences and heterogeneous skeletal affinity for bisphosphonate
based on whole body fluorimetry in this rat model. Higher bisphosphonate signal intensity
displayed by axial bone (Figure 2E) is apparently size-dependent because the vertebral
bones are larger and demonstrated higher bisphosphonate per unit calcium than oral and
appendicular bones (Figure 3E). But the quantitatively higher bisphosphonate released from
oral bone may be related to higher hydroxyapatite content (Figures 3B and 3D) that
translates into higher jaw bone affinity for bisphosphonate. Thus, our results support
assertions that mandible is structurally denser than axial and appendicular bones and display
higher skeletal bisphosphonate uptake.
Bisphosphonate skeletal accumulation is also influenced by rate of liberation from bone.
Bone with higher remodeling ability preferentially accumulates more bisphosphonate due to
greater amount of actively resorbing surface that favors bisphosphonate binding (Bauss et
al., 2002, Sato et al., 1991). However hydroxyapatite-bound bisphosphonate is also
continuously liberated in rapidly remodeling bone owing to the locally acidic environment
produced by osteoclasts (Sato et al., 1991). Also sites with high remodeling activity have
greater metabolic demands and higher blood flow that favor rapid elimination of
bisphosphonate. Our analysis of oral, axial and appendicular bones supports site-disparity in
bisphosphonate dissociation. It showed clearly that bisphosphonate was readily liberated
mostly from the jaw bones (Figure 3) supporting the theory of higher jaw bone remodeling
relative to non-oral sites (Huja et al., 2006). Therefore, a potentially more rapid release of
jaw-bound bisphosphonate translates to reduced bisphosphonate therapeutic efficacy in the
jaws. Consequent reduction in bisphosphonate anti-resorptive action can predispose jaw
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bones to higher osteoclast mediated bone resorption. Pamidronate has also been shown to be
more toxic to jaw osteoprogenitor cells (Stefanik et al., 2008), so rise in osteoclast
recruitment combined with reduction in number of osteoprogenitor cells will uncouple
osteoblast-osteoclast balance (Sarin et al., 2008). An increase in jaw bone resorption without
compensatory bone formation favors regional bone death. Prior exposure of jaw bone to
bisphosphonate also supports progression of BJON since high bisphosphonate concentration
causes direct toxicity to osteocytes, osteoblasts and osteogenic precursors (Idris et al., 2008,
Stefanik et al., 2008, Stefanik et al., 2006). Therefore, focal loss of osteocytes and canaliculi
network (Allen & Burr, 2008, Hansen et al., 2006) can promote accumulation of regions of
dead osteocytes and non-viable bone over time (Allen, 2009a).
The limitations of this pilot study must be noted. Nude skin of athymic rats minimizes
interference with optical imaging but assessing the added effects of immune surveillance
was not practicable in athymic rats. Pamidronate metabolic dose of 60.7 μg/kg body weight
is less than human doses (Allen, 2009b, Fuchs et al., 2008), but it is clinically relevant
considering that serum concentration of pamidronate is 2.5 μg/ml 4 hours after infusion
[(Stefanik et al., 2008); United States Package Insert; Novartis Pharmaceuticals].
Notwithstanding, a dose of bisphosphonate that is 30 times less than human doses has been
associated with jaw osteonecrosis in another rat model (Allen, 2009b, Sonis et al., 2009). An
earlier study evaluated subcutaneously administered ibandronate in a single rat but reported
no site differences in ibandronate uptake (Bauss et al., 2008); the current study advanced our
understanding of site-disparity in skeletal uptake and release of bisphosphonate using four,
although limited, number of athymic rats. Future work in immunocompetent animals will
further clarify the roles of immune surveillance in the initiation of BJON. Additionally,
optical imaging modality supports acquisition of two-dimensional planar images with
limited anatomical detail compared to structural imaging modalities like micro-computed
tomography (micro-CT). However, future evaluation of site differences with three-
dimensional optical tomography, micro-CT and histological evaluation of depth of
bisphosphonate penetration will provide more structural detail of hydroxyapatite-bound
bisphosphonate. This study did not assess the whole skeleton; also teeth, proximal and distal
ends of long bones were excluded to minimize confounding effects. Finally, serial
decalcification with EDTA is a simulation of locally acidic environment in osteoclast-
mediated bone resorption and analysis of calcium-bound bisphosphonate is an indirect
assessment of hydroxyapatite-bound bisphosphonate. Therefore, further studies using larger
samples and more specialized equipments will give additional insights on the impact of
disproportionate regional bisphosphonate skeletal uptake and liberation on the pathogenesis
of BJON.
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Figure 1.
Experimental outline
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Figure 2.
In vivo optical imaging of hydroxyapatite-bound bisphosphonate. Representative ventral
view of the whole body of a rat (A) showing signal intensity of regional skeletal uptake of
fluorescently labeled bisphosphonate. Following dissection, representative in vitro images
demonstrated variable bisphosphonate skeletal uptake. The mandible [oral bone] was
displayed strong intensity in the body (B, clear arrows) and condyles (B, solid arrows).
Similarly, signal intensity was stronger in the proximal and distal ends relative to the
diaphysis of the long bones [appendicular bones] (C). Signal intensity was heterogeneous in
the ribs and vertebra [axial bones] (D). Analysis of regional signal intensity in the animals
showed variable skeletal uptake as presented in the box and whisker plots (E) [n = 4; median
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is the line within the box; the ends of the boxes define 25th and 75th percentiles; the two bars
outside the box define 10th and 90th percentiles].
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Figure 3.
Regional variability in skeletal uptake and release of fluorescently labeled bisphosphonate.
Time-dependent release of hydroxyapatite-bound bisphosphonate (A) and calcium (C) as
well as total bisphosphonate (B) and calcium (D) released were significantly highest in oral
bones relative to axial and appendicular sites (p < 0.05); an indication that bisphosphonate
can be readily liberated from the mandible due to the ease of calcium release.
Bisphosphonate per unit calcium (E) was highest in axial bone relative to oral and
appendicular bones [n = 4; median is the line within the box; the ends of the boxes define
25th and 75th percentiles; the two bars outside the box define 10th and 90th percentiles].
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Table 1
Calculation of metabolic dose of pamidronate injected in rats relative to human dose of 60 mg pamidronate
(Allen, 2009b, Fuchs et al., 2008)
Rat pamidronate metabolic dose relative to humans*
Rat Human
Body weight (Kg) 0.25 60 70
Metabolic weight (kg) = [actual weight]0.75 0.354 22 24.2
Drug dose injected (μg/kg body weight) 86 1000 857.1
Actual dose (μg) = dose/[1/body weight] 21.5 60000 5999.7
Metabolic dose (μg/kg) = actual dose/metabolic weight) 60.7 2727.3 2479.2
*
Calculations based on rat dose of 80 nmol/kg body weight and 60 mg dose in humans (Allen, R.W. 2009: Fuchs, R.K. 2008)
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